PMS-METOPROLOL-L TABLET
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
24-09-2020
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
METOPROLOL TARTRATE
Available from:
PHARMASCIENCE INC
ATC code:
C07AB02
INN (International Name):
METOPROLOL
Dosage:
50MG
Pharmaceutical form:
TABLET
Composition:
METOPROLOL TARTRATE 50MG
Administration route:
ORAL
Units in package:
100/500/1000
Prescription type:
Prescription
Therapeutic area:
BETA-ADRENERGIC BLOCKING AGENTS
Product summary:
Active ingredient group (AIG) number: 0111923002; AHFS:
Authorization status:
APPROVED
Authorization date:
1997-03-10
Summary of Product characteristics
PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................
Read the complete document
